Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Next revisionBoth sides next revision | ||
| mrepo:46draft [05/12/2019 @ 15:56] – [Insight 46] adammoore | mrepo:46draft [06/12/2019 @ 15:14] – adammoore | ||
|---|---|---|---|
| Line 5: | Line 5: | ||
| Insight 46 is a neuroscience sub-study of the NSHD. Launched in 2015, Insight 46 recruited 502 study members selected at random from those who attended a clinical visit at 60–64 years and on whom relevant life course data are available. The study aims to investigate how life course factors and genetics influence the development of brain pathologies and impact on cognition, and so to provide insights into healthy brain ageing and the development of dementia. | Insight 46 is a neuroscience sub-study of the NSHD. Launched in 2015, Insight 46 recruited 502 study members selected at random from those who attended a clinical visit at 60–64 years and on whom relevant life course data are available. The study aims to investigate how life course factors and genetics influence the development of brain pathologies and impact on cognition, and so to provide insights into healthy brain ageing and the development of dementia. | ||
| - | For Insight 46, participants attended two clinic visits, two years apart. Each visit consists of a combination of brain imaging, biosampling and clinical interview, including: | + | For Insight 46, participants attended two clinic visits, two years apart. Each visit consists of a combination of brain imaging, biosampling and a clinical interview, including: |
| * Multi-modal MR imaging with concurrent acquisition of b-amyloid PET scanning. | * Multi-modal MR imaging with concurrent acquisition of b-amyloid PET scanning. | ||
| Line 33: | Line 33: | ||
| * {{Medication.pdf|Medication}} usage | * {{Medication.pdf|Medication}} usage | ||
| * Cognitive test results - including {{ad8.pdf|ad8}}, | * Cognitive test results - including {{ad8.pdf|ad8}}, | ||
| - | * {{Audiometry.pdf|Audiometry}} | + | * {{Audiometry.pdf|Audiometry}} |
| \\ \\ | \\ \\ | ||
| ---- | ---- | ||
| - | Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, | + | Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, |